Physician profile
Sabahat Bokhari
NPI 1831288158
$578,243.39
in general payments reported to CMS, 2019-2025
16 companies · $282K in 2025
The $282K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $14K · 2021: $26K · 2022: $5,465 · 2023: $14K · 2024: $194K · 2025: $282K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $406K · Consulting Fee: $42K · Travel and Lodging: $31K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $406,261.16 |
| Consulting Fee | $41,888.75 |
| Travel and Lodging | $30,746.61 |
| Food and Beverage | $11,113.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $242,176.63 | 2021-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals Lp | $123,158.06 | 2023-2025 | Wainua |
| Pfizer INC. | $104,750.31 | 2019-2025 | |
| Bridgebio Pharma, INC. | $65,357.32 | 2025 | Attruby |
| Astellas Pharma US INC | $23,030.75 | 2019-2023 | Lexiscan |
| E.R. Squibb & Sons, L.L.C. | $15,843.44 | 2023-2025 | Camzyos, Eliquis |
| Alexion Pharmaceuticals, INC. | $1,925.00 | 2025 | |
| Pfizer International LLC | $1,800.00 | 2020 | |
| Abbott Laboratories | $137.17 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Tempus Ai, INC | $27.75 | 2025 | Xt Cdx |
| Lantheus Medical Imaging, INC. | $19.15 | 2024 | |
| Boston Scientific Corporation | $17.81 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabahat Bokhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.